Emerson reports Q1 adjusted EPS of $1.40, below consensus estimate of $1.50.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy EMR?
Q1 Revenue Growth: The company reported a 4% increase in revenue for the first quarter.
Long-term Growth Trends: Karsanbhai emphasized that their portfolio is aligned with sustainable growth trends, leading to consistent mid-single-digit order growth over the past three quarters.
Sales Expectations: The positive trends support the company's sales expectations for 2026 and beyond.
Shareholder Value Creation: The company remains confident in its operational execution and plans to return cash to shareholders, aiming for further value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMR
Wall Street analysts forecast EMR stock price to rise
14 Analyst Rating
7 Buy
6 Hold
1 Sell
Moderate Buy
Current: 146.770
Low
125.00
Averages
150.46
High
170.00
Current: 146.770
Low
125.00
Averages
150.46
High
170.00
About EMR
Emerson Electric Co. is a global technology and software company that provides solutions for customers in a wide range of end markets around the world. The Company operates through seven segments under two business groups, such as Intelligent Devices and Software and Control. Its Intelligent Devices business includes Final Control, Measurement & Analytical, Discrete Automation, and Safety & Productivity. Software and Control business includes Control Systems & Software, Test & Measurement, and AspenTech. Its Final Control segment is a global provider of control valves, isolation valves, shutoff valves, pressure relief valves, pressure safety valves, actuators, and regulators for process and hybrid industries. Its Measurement & Analytical segment is a supplier of intelligent instrumentation measuring the physical properties of liquids or gases. AspenTech segment provides asset optimization software that enables industrial manufacturers to design, operate and maintain their operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emerson to Report Q2 Results on May 5, 2026
- Earnings Release Schedule: Emerson is set to release its second-quarter financial results after market close on May 5, 2026, which is expected to significantly impact investor sentiment.
- Investor Conference Call: On the same day, Emerson's senior management will hold a conference call at 4:30 p.m. Eastern Time to discuss the results, providing in-depth analysis and future outlook.
- Online Participation: Interested parties can register through Emerson's Investor Relations website to listen to the call and view presentation slides posted in advance, enhancing transparency and accessibility.
- Disclosure Channels: Emerson uses its Investor Relations website as a primary means of disclosing material information to investors, ensuring compliance with regulatory obligations and keeping stakeholders informed.
See More
Investment Outlook for Honeywell and Emerson
- Dividend Appeal: Emerson Electric has raised its dividend for 69 consecutive years, making it one of the Dividend Kings, while Honeywell has increased its payout for 15 years, offering yields of 1.50% and 2% respectively, attracting income-seeking investors.
- Transformation Strategy: Honeywell is undergoing a significant transformation, planning to spin off its aerospace division in Q3, with analysts suggesting this move could unlock 'sum-of-the-parts' value for investors, allowing a sharper focus on industrial automation.
- Market Positioning: Emerson's transformation is largely complete, focusing on industrial automation and intelligent devices to help factories and power plants automate operations, appealing to conservative investors, while Honeywell is still in transition, suitable for those optimistic about its future potential.
- Valuation Comparison: Both companies share similar valuations on a forward earnings basis, so investors should choose based on personal investment goals, with Emerson being ideal for those seeking reliable income and Honeywell for those betting on its spinoff unlocking hidden value.
See More
Industrial Companies Transforming for Dividend Appeal
- Dividend Appeal: Honeywell and Emerson Electric, as leaders in industrial automation, provide steady cash flow and reliable dividends, with Honeywell offering a 2% yield and Emerson increasing dividends for 69 consecutive years, attracting income-seeking investors.
- Business Transformation: Honeywell is transforming into a software-integrated industrial giant, planning to spin off its aerospace division in Q3, a move analysts believe could unlock 'sum-of-the-parts' value for investors and enhance competitiveness in high-growth sectors.
- Market Environment: Amid the Dow Jones Industrial Average entering correction territory, companies with physical assets and essential infrastructure stand out for their pricing power and steady cash flow, with Honeywell and Emerson exemplifying this trend.
- Investment Choices: Emerson's transformation is largely complete, making it a pure play on the fourth industrial revolution and appealing to conservative investors, while Honeywell is still in transition, suitable for those optimistic about its future potential.
See More
Pharmaceutical Industry Accelerates AI Compliance Transformation
- AI-Driven Compliance Monitoring: Pharmaceutical manufacturers are shifting towards AI-driven real-time monitoring systems that dynamically assess compliance throughout the production process, thereby reducing human error and enhancing data integrity to meet increasingly stringent regulatory demands.
- FDA Support for New Technologies: The U.S. FDA encourages the adoption of advanced manufacturing technologies and continuous production models, which is driving the pharmaceutical industry towards intelligent, automated compliance infrastructures, reducing the risk of manufacturing failures and supply disruptions.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant evolution in pharmaceutical development and manufacturing, integrating AI, robotics, and advanced analytics to enhance productivity and product quality while promoting data-driven decision-making.
- Significant Market Potential: The global pharmaceutical manufacturing market is expected to reach $1 trillion, with investments increasingly directed towards automation and digital infrastructure, indicating a strategic shift in companies' focus towards compliance and efficiency.
See More
Pharmaceutical Industry Shifts to AI-Driven Compliance
- AI-Driven Compliance Transformation: Pharmaceutical manufacturers are increasingly integrating artificial intelligence into production workflows for real-time compliance monitoring, replacing traditional manual checks and retrospective audits, thereby enhancing production efficiency and reducing human error risks.
- FDA Support for New Technologies: The U.S. Food and Drug Administration (FDA) is promoting the adoption of advanced manufacturing technologies, encouraging companies to implement real-time data monitoring to ensure product quality and minimize manufacturing failure risks, which introduces new compliance standards for the industry.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant transformation in the pharmaceutical industry, integrating artificial intelligence, robotics, and data analytics to enhance production efficiency and product quality while driving data-driven decision-making processes.
- Significant Market Potential: The global pharmaceutical manufacturing market is projected to reach $1 trillion, with increasing investments in automation and digital infrastructure, indicating the industry's focus on intelligent manufacturing and compliance will drive sustainable growth.
See More
Emerson Supports First Biomass Carbon Capture Facility
- Project Scale and Investment: Strategic Biofuels is investing $2 billion in its Louisiana Green Fuels facility, which will convert 1.3 million tons of forestry residuals into renewable power annually, demonstrating a strong commitment to sustainable energy.
- Carbon Capture Capacity: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year in secure geological formations nearly a mile underground, positioning Louisiana as a leader in carbon-neutral energy production.
- Automation Technology Application: Emerson will deploy its DeltaV™ Automation Platform along with a suite of advanced automation and measurement technologies to optimize the plant's integrated operations, ensuring timely project completion and enhanced operational efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer highlighted that the project will not only convert waste biomass into reliable power but also permanently remove carbon from the atmosphere through carbon capture technology, driving the future of clean energy.
See More
Emerson to Report Q2 Results on May 5, 2026
- Earnings Release Schedule: Emerson is set to release its second-quarter financial results after market close on May 5, 2026, which is expected to significantly impact investor sentiment.
- Investor Conference Call: On the same day, Emerson's senior management will hold a conference call at 4:30 p.m. Eastern Time to discuss the results, providing in-depth analysis and future outlook.
- Online Participation: Interested parties can register through Emerson's Investor Relations website to listen to the call and view presentation slides posted in advance, enhancing transparency and accessibility.
- Disclosure Channels: Emerson uses its Investor Relations website as a primary means of disclosing material information to investors, ensuring compliance with regulatory obligations and keeping stakeholders informed.
See More
Investment Outlook for Honeywell and Emerson
- Dividend Appeal: Emerson Electric has raised its dividend for 69 consecutive years, making it one of the Dividend Kings, while Honeywell has increased its payout for 15 years, offering yields of 1.50% and 2% respectively, attracting income-seeking investors.
- Transformation Strategy: Honeywell is undergoing a significant transformation, planning to spin off its aerospace division in Q3, with analysts suggesting this move could unlock 'sum-of-the-parts' value for investors, allowing a sharper focus on industrial automation.
- Market Positioning: Emerson's transformation is largely complete, focusing on industrial automation and intelligent devices to help factories and power plants automate operations, appealing to conservative investors, while Honeywell is still in transition, suitable for those optimistic about its future potential.
- Valuation Comparison: Both companies share similar valuations on a forward earnings basis, so investors should choose based on personal investment goals, with Emerson being ideal for those seeking reliable income and Honeywell for those betting on its spinoff unlocking hidden value.
See More
Industrial Companies Transforming for Dividend Appeal
- Dividend Appeal: Honeywell and Emerson Electric, as leaders in industrial automation, provide steady cash flow and reliable dividends, with Honeywell offering a 2% yield and Emerson increasing dividends for 69 consecutive years, attracting income-seeking investors.
- Business Transformation: Honeywell is transforming into a software-integrated industrial giant, planning to spin off its aerospace division in Q3, a move analysts believe could unlock 'sum-of-the-parts' value for investors and enhance competitiveness in high-growth sectors.
- Market Environment: Amid the Dow Jones Industrial Average entering correction territory, companies with physical assets and essential infrastructure stand out for their pricing power and steady cash flow, with Honeywell and Emerson exemplifying this trend.
- Investment Choices: Emerson's transformation is largely complete, making it a pure play on the fourth industrial revolution and appealing to conservative investors, while Honeywell is still in transition, suitable for those optimistic about its future potential.
See More
Pharmaceutical Industry Accelerates AI Compliance Transformation
- AI-Driven Compliance Monitoring: Pharmaceutical manufacturers are shifting towards AI-driven real-time monitoring systems that dynamically assess compliance throughout the production process, thereby reducing human error and enhancing data integrity to meet increasingly stringent regulatory demands.
- FDA Support for New Technologies: The U.S. FDA encourages the adoption of advanced manufacturing technologies and continuous production models, which is driving the pharmaceutical industry towards intelligent, automated compliance infrastructures, reducing the risk of manufacturing failures and supply disruptions.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant evolution in pharmaceutical development and manufacturing, integrating AI, robotics, and advanced analytics to enhance productivity and product quality while promoting data-driven decision-making.
- Significant Market Potential: The global pharmaceutical manufacturing market is expected to reach $1 trillion, with investments increasingly directed towards automation and digital infrastructure, indicating a strategic shift in companies' focus towards compliance and efficiency.
See More
Pharmaceutical Industry Shifts to AI-Driven Compliance
- AI-Driven Compliance Transformation: Pharmaceutical manufacturers are increasingly integrating artificial intelligence into production workflows for real-time compliance monitoring, replacing traditional manual checks and retrospective audits, thereby enhancing production efficiency and reducing human error risks.
- FDA Support for New Technologies: The U.S. Food and Drug Administration (FDA) is promoting the adoption of advanced manufacturing technologies, encouraging companies to implement real-time data monitoring to ensure product quality and minimize manufacturing failure risks, which introduces new compliance standards for the industry.
- Rise of Pharma 4.0: The emergence of the Pharma 4.0 concept signifies a significant transformation in the pharmaceutical industry, integrating artificial intelligence, robotics, and data analytics to enhance production efficiency and product quality while driving data-driven decision-making processes.
- Significant Market Potential: The global pharmaceutical manufacturing market is projected to reach $1 trillion, with increasing investments in automation and digital infrastructure, indicating the industry's focus on intelligent manufacturing and compliance will drive sustainable growth.
See More
Emerson Supports First Biomass Carbon Capture Facility
- Project Scale and Investment: Strategic Biofuels is investing $2 billion in its Louisiana Green Fuels facility, which will convert 1.3 million tons of forestry residuals into renewable power annually, demonstrating a strong commitment to sustainable energy.
- Carbon Capture Capacity: The facility will capture and permanently store 1.1 million metric tons of CO₂ each year in secure geological formations nearly a mile underground, positioning Louisiana as a leader in carbon-neutral energy production.
- Automation Technology Application: Emerson will deploy its DeltaV™ Automation Platform along with a suite of advanced automation and measurement technologies to optimize the plant's integrated operations, ensuring timely project completion and enhanced operational efficiency.
- Sustainability Strategy: Emerson's Chief Sustainability Officer highlighted that the project will not only convert waste biomass into reliable power but also permanently remove carbon from the atmosphere through carbon capture technology, driving the future of clean energy.
See More
